$ZVRA insider trading
Over the last 12 months, Zevra Therapeutics insiders reported 2 buys totaling $183K and 12 sales totaling $2.5M across SEC Form 4 filings. 79% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $183K 2 events
- Sold · 12m
- $2.5M 12 events
- Events · 12m
- 14 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 79% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Thompson RahsaanChief Legal & Compliance · O | ▼ Sale | 42,666 | $11.13 | $475K | -53.2% | plan |
| Aug 10, 2026 | Watton Corey MichaelD | ▼ Sale | 12,300 | $11.25 | $138K | -87.2% | — |
| Jun 22, 2026 | Thompson RahsaanChief Legal & Compliance · O | ▼ Sale | 34,557 | $12.68 | $438K | -30.1% | plan |
| Feb 9, 2026 | McFarlane Neil F.President and CEO · O·D | ▼ Sale | 14,625 | $8.56 | $125K | -3.6% | plan |
| Feb 3, 2026 | Schafer JoshuaCCO · O | ▼ Sale | 10,500 | $9.19 | $97K | -14.4% | plan |
| Feb 3, 2026 | Sangiovanni Timothy J.SVP, Finance & Corp Controller · O | ▼ Sale | 3,000 | $9.18 | $28K | -9.2% | plan |
| Feb 2, 2026 | McFarlane Neil F.President and CEO · O·D | ▼ Sale | 91,000 | $9.38 | $853K | -20% | plan |
| Jan 30, 2026 | Schafer JoshuaCCO · O | ▼ Sale | 3,375 | $8.83 | $30K | -8.3% | plan |
| Jan 30, 2026 | Quartel Adrian WChief Medical Officer · O | ▼ Sale | 4,533 | $8.83 | $40K | -31.8% | plan |
| Jan 30, 2026 | Thompson RahsaanChief Legal & Compliance · O | ▼ Sale | 4,080 | $8.83 | $36K | -7.6% | plan |
| Jan 30, 2026 | Sangiovanni Timothy J.SVP, Finance & Corp Controller · O | ▼ Sale | 1,750 | $8.82 | $15K | -7.7% | plan |
| Oct 10, 2025 | McFarlane Neil F.President and CEO · O·D | ▼ Sale | 19,500 | $10.82 | $211K | -8.1% | plan |
| Sep 12, 2025 | FAVORITO TAMARA AD | ▲ Buy | 3,175 | $7.79 | $25K | +441.6% | — |
| Sep 12, 2025 | Shih AlvinD | ▲ Buy | 20,000 | $7.89 | $158K | — | — |
| Aug 19, 2025 | Bode John BD | ▲ Buy | 5,000 | $9.16 | $46K | +12.5% | — |
Every $ZVRA filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Zevra Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ZVRA feed.